MOTS-c Side Effects: What Is Known and What Is Not

MOTS-c Side Effects: What Has Been Measured in Humans

Search for MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide side effects and the same short list comes back everywhere: injection-site redness, a tired first week, the odd headache, mild nausea. None of those lists has a number behind it, because no trial of injected MOTS-c in people has ever reported results. When the FDA evaluated MOTS-c for the compounding bulks list, its review dated May 11, 2026 said the agency had not identified "any clinical studies or human exposure data for MOTS-c via any route of administration," and concluded that the potential safety risks in humans "are unknown." The evidence that does exist sorts into four tiers, and keeping them apart is most of the work of reading about this peptide honestly.

The second row is the only time a MOTS-c-type molecule has gone into people under trial conditions. CohBar, a company co-founded by the senior author of the MOTS-c discovery paper, built a modified analog called CB4211. The safety story started early. In November 2018 the company suspended dosing to address injection-site reactions it called mild but "unexpectedly persistent," described as painless bumps that could be felt under the skin. Dosing later resumed, and the study finished in April 2021.

Topline results came by press release in August 2021. In the four-week Phase 1b portion, 20 adults with obesity and fatty liver disease received 25 mg of CB4211 under the skin daily (11 people) or placebo (9). The company reported no serious adverse events, and the only adverse events in more than 10% of treated subjects were injection-site reactions described as transient and generally mild to moderate. The results were never published in a journal, the registry record shows no posted results, and CohBar moved to liquidate in late 2023.

CohBar, Inc. "A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease." ClinicalTrials.gov identifier NCT03998514. Completed April 2021; no results posted to the registry. View study

Two cautions. CB4211 was engineered to behave better as a drug than the natural peptide, so its tolerability is only a hint about MOTS-c. And eleven treated people over four weeks cannot surface anything rare or slow. What the program does establish is that the one effect a MOTS-c-type injection has reliably produced in humans is a local skin reaction.

The first row is finally changing. A randomized, placebo-controlled Phase 2a study of MOTS-c itself (NCT07505745) began recruiting in February 2026: adults with prediabetes and overweight or obesity, a daily subcutaneous dose for 12 weeks, about 120 participants planned. Treatment-emergent adverse events through week 16 are a primary outcome, which makes it the first study built to count MOTS-c side effects in people. Primary completion is estimated for February 2027. The wider evidence picture lives in our MOTS-c guide Read nextMOTS-c Dosage Chart: Units, Protocols & EffectsMOTS-c is the 16-amino-acid mitochondrial peptide your body releases during exercise. This guide leads with what most readers came for: a real dosage chart with per-injection amounts, insulin syringe unit conversions, weekly totals, and cycle lengths. Then it covers the AMPK mechanism, the metformin comparison, the 2015 USC discovery story, and an honest read of the evidence.Read article , and MOTS-c benefits Read nextMOTS-c Benefits: What the Evidence SupportsAlmost every benefit attributed to MOTS-c traces back to a mouse, a cell culture, or a blood test measuring the peptide your own mitochondria already make. This page grades each claim by what was measured, what it was measured in, and whether anyone has given injected MOTS-c to a person and looked.Read article grades each claimed effect by what was actually measured.

What Users Report (Anecdote, Labelled as Such)

With no trial to consult, what circulates online is user report. The most useful public summary comes from an unexpected source, the US Anti-Doping Agency, which notes that "among people who claim to purchase MOTS-c online, there are many reported side effects, including increased heart rate or heart palpitations, injection site irritation, insomnia, local or generalized immune reactions, and fever." The caveats are built into that sentence. These are people who claim to have bought MOTS-c online, with nobody verifying what was in the vial or how much they injected. A fever after injecting an untested research powder says as much about endotoxin and technique as about the peptide.

Several of these are tangled up with how MOTS-c is used. Protocols often place the injection in a fasted morning window or shortly before training, and a fasted workout can produce a headache and a flat afternoon with no peptide involved. One theory popular online blames the slump on folate, since in cell studies MOTS-c acts by inhibiting the folate cycle on its way to activating AMPK. Nobody has measured folate status, or fatigue, in a person given MOTS-c, so treat it as a guess. The baseline across injectable peptides is in the peptide side effects guide Read nextPeptide Side Effects: Normal vs. Red Flag (2026)Most peptide side effects are mild local reactions that resolve in a day. A smaller set of systemic effects depends on the pathway the peptide acts on. And a third category, the one worth paying attention to, points to a problem with the product or the patient that should pause the protocol. Here is how to tell them apart.Read article , and site rotation is covered in where to inject MOTS-c Read nextWhere to Inject MOTS-c: Sites, Rotation, TimingMOTS-c is a subcutaneous injection. The four standard sites work, but rotation, timing relative to exercise, and a few small technique details meaningfully change comfort and consistency. Here is the practical guide patients ask for after their first vial arrives.Read article .

Lee C, Zeng J, Drew BG, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism. 2015;21(3):443-454. PMID 25738459. View study

What FDA Reviewers Flagged in 2026

The evaluation FDA staff prepared for the July 2026 advisory committee meeting is the most thorough public safety review of MOTS-c that exists. Its central finding is a list of blanks.

Immunogenicity is the least intuitive item on that list. An immune response to an injected peptide can be silent, can blunt the peptide’s effect over time, or, in the agency’s general description of peptide products, can produce antibodies that neutralize the body’s own version of the molecule. MOTS-c is something your mitochondria already make, and nobody has looked for anti-MOTS-c antibodies in anyone. Much of the risk tracks product quality. Reviewers named aggregates and synthesis impurities, and observed that most certificates of analysis for MOTS-c list a purity figure with nothing on either. Our guide to reading a peptide COA Read nextHow to Read a Peptide COAA Certificate of Analysis is the lab report behind a peptide vial. Learn to read one line by line: identity, purity, net peptide content, sterility, and endotoxin. Then learn the red flags that separate a real prescription COA from the screenshot a gray-market vendor pastes into a product page.Read article covers what that testing does and does not show.

None of this stopped the committee. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 7 to 5, with two abstentions, to recommend MOTS-c for the 503A bulks list, against the staff position. The vote is advisory, the agency has finalized nothing as of September 2026, and MOTS-c remains unapproved for any use. More in is MOTS-c FDA approved Read nextIs MOTS-c FDA Approved? Mitochondrial Peptide StatusNo. MOTS-C was only discovered in 2015. It is the newest peptide in clinical use and the first peptide ever found to be encoded by mitochondrial DNA rather than nuclear DNA. That discovery, from Changhan David Lee's lab at USC, upended decades of assumptions about where bioactive peptides come from. Here is what we know so far.Read article and our write-up of the FDA panel vote Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe FDA's Pharmacy Compounding Advisory Committee finished its two-day meeting on July 24, 2026. By the end, it had voted to recommend six of the seven peptides on the agenda for the 503A compounding list, including BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and against just one, Emideltide (DSIP). Every vote went against the FDA's own scientists. Here is the full tally, what it changes, and what it does not.Read article .

U.S. Food and Drug Administration. "FDA Briefing Document for MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate)." Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. Evaluation dated May 11, 2026. View study

Knoop A, Thomas A, Thevis M. "Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes." Rapid Communications in Mass Spectrometry. 2019;33(4):371-380. PMID 30394592. View study

MOTS-c and Blood Sugar: The Interaction to Plan For

If one MOTS-c side effect deserves planning, it is low blood sugar in people already taking something that lowers it. The evidence is indirect, so here is the chain. MOTS-c activates AMPK, the same energy-sensing switch metformin works through. In the 2015 discovery study it prevented diet-induced and age-related insulin resistance in mice. In the CB4211 trial, glucose fell 6% in the treated group against no change on placebo after four weeks. Layer that on insulin or a sulfonylurea, drugs that can cause hypoglycemia by themselves, and you have a combination nobody has studied.

Timing sharpens the concern. Many protocols put the dose in a fasted morning window or 30 to 60 minutes before exercise, the two situations where blood sugar already runs lowest. Shakiness, sweating, sudden hunger, a pounding heartbeat or foggy thinking after a dose are the symptoms to recognize, and a reason to eat fast-acting carbohydrate instead of pushing through the workout.

This is why the intake form asks about diabetes medication. List insulin, sulfonylureas, metformin, SGLT2 inhibitors and GLP-1 medications so the reviewing provider can judge whether MOTS-c is appropriate alongside them. Nothing here is a reason to change a diabetes drug. Two pairings have their own pages, MOTS-c vs metformin Read nextMOTS-c vs. Metformin: Peptide or the Pill?Both MOTS-c and metformin flip the same cellular switch: AMPK, the master sensor that turns on during exercise and fasting. That shared mechanism is why they keep getting compared in longevity circles. But one is a decades-old, oral, FDA-approved diabetes drug used off-label, and the other is a mitochondrial peptide given as a subcutaneous injection. This guide breaks down how each works, where the human evidence actually stands, and why the honest answer is not either-or.Read article and MOTS-c with semaglutide Read nextMOTS-c and Semaglutide: Can You Combine Them?Ask this question online and you get two kinds of answers. Retail sites say yes and quote fat-loss percentages that do not exist anywhere in the literature. Cautious sites say nothing has been studied and stop there. Both halves are doing part of the job. This page does the whole thing: what is actually known, including the analog trial almost nobody mentions, and how a prescribing clinic thinks about the combination in practice.Read article , and the short version of both is that no human study has tested the combination.

MOTS-c Side Effects and Cancer: What Has Been Studied

A peptide that flips a master metabolic switch and enters the cell nucleus sounds like something a tumor might care about, so the question is fair. Start with what is missing. The FDA review identified no carcinogenicity studies and no genotoxicity studies of MOTS-c. Regulators normally expect carcinogenicity work for a drug meant to be used for six months or more, continuously or in repeated courses, and for MOTS-c it has never been done.

The laboratory signals that exist point in different directions. In a 2024 study, MOTS-c levels were lower in blood and tumor tissue from ovarian cancer patients, and giving MOTS-c to cancer cells and tumor-bearing mice slowed growth, with no systemic toxicity reported in the animals. That is one group, one cancer type, lab models. Against it sits a 2018 cell study from the USC group behind the discovery: in human fibroblasts pushed into senescence, adding MOTS-c modestly increased parts of the inflammatory mix those cells secrete. And AMPK is a known two-way street in cancer biology. It restrains growth signaling, yet it can also help established tumor cells survive energy stress. A 2013 review in Cancer Research put the question in its title: "AMPK: a contextual oncogene or tumor suppressor?"

Yin Y, Li Y, Ma B, et al. "Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination." Advanced Science. 2024;11(43):e2405620. PMID 39321430. View study

Kim SJ, Mehta HH, Wan J, et al. "Mitochondrial peptides modulate mitochondrial function during cellular senescence." Aging (Albany NY). 2018;10(6):1239-1256. PMID 29886458. View study

Liang J, Mills GB. "AMPK: a contextual oncogene or tumor suppressor?" Cancer Research. 2013;73(10):2929-2935. PMID 23644529. View study

The human study most often cited here says less than people assume. Dieli-Conwright and colleagues measured the body’s own MOTS-c in breast cancer survivors during a 16-week exercise program. Nobody was injected with anything, so it says nothing about giving MOTS-c to someone with a cancer history.

Dieli-Conwright CM, Sami N, Norris MK, et al. "Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors." Scientific Reports. 2021;11(1):16916. PMID 34413391. View study

Put together: no evidence that MOTS-c causes or accelerates cancer, no evidence that it protects against it, and no study capable of settling either. A seller describing it as anti-cancer is a full category of research ahead of the data. The screening question about active or recent malignancy exists because of this uncertainty. When a mechanism touches growth and energy pathways and the toxicology is blank, someone in or near cancer treatment should not add it without their oncologist involved.

Heart Rate, Palpitations, and the Heart Question

The palpitation reports above drive most heart-related searches. The published heart research concerns the body’s own MOTS-c or rodents. A Mayo Clinic group found lower circulating MOTS-c in patients with coronary endothelial dysfunction, which is an observation about a biomarker. No study has tracked heart rate, rhythm or blood pressure in people given MOTS-c. The CB4211 trial listed vital signs and 12-lead ECGs among its primary safety measures and the company reported no serious adverse events, but no cardiac data were ever published.

Qin Q, Delrio S, Wan J, et al. "Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction." International Journal of Cardiology. 2018;254:23-27. PMID 29242099. View study

So a racing heart after a dose has three plausible explanations nobody can rank: the peptide, a dip in blood sugar, or something else in an unverified vial. Whatever the cause, palpitations that persist, chest pain, fainting or shortness of breath mean stop and get medical care the same day. An existing rhythm problem or heart disease belongs on your intake.

MOTS-c Long-Term Side Effects: The Honest Unknown

Long-term is where the blank is widest: no human exposure data at any duration, no repeat-dose animal toxicology, no carcinogenicity work. Nobody can describe what a year of MOTS-c does. Clinic protocols typically run 8 to 12 weeks followed by a break, and that structure is precautionary. Sustained AMPK activation by this route has never been studied, and a scheduled stop creates a natural point to reassess. Immunogenicity is the long-run issue that gets the least attention: if antibodies form, the likeliest consequence is a peptide that quietly stops working. Our look at peptide long-term safety Read nextAre Peptides Safe Long-Term? What the Data SaysMost safety questions about peptides assume the timeframe is one or two cycles. The harder question is what happens after a year, three years, or a decade. The honest answer is that peptides fall into three buckets: ones with multi-decade clinical data, ones with several years of safety record but limited long-term studies, and ones where the long-term picture is genuinely incomplete. Here is the bucket each peptide is in and what monitoring matters.Read article puts MOTS-c in the group with the least accumulated human experience.

What to Watch For in the First Weeks

Who Gets Screened Out, and Why

With no human safety database, the exclusion logic runs on mechanism and on missing evidence. The screening flags below are what tends to get an intake declined, or sent back with questions, along with the reasoning behind each one.

Kong BS, Min SH, Lee C, Cho YM. "Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes." Cell Reports. 2021;36(4):109447. PMID 34320351. View study

A flag is the start of a decision, and the licensed provider reviewing your history makes the final call. What that review looks at is laid out in what providers review before prescribing Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. There is a specific list they run down before any peptide is approved: the conditions that change whether a peptide is safe, the medication classes that have to be cross-checked, and the reasons an order gets sent back or declined. Here is that list, from the provider’s side of the screen.Read article .

MOTS-c

Half of what FDA reviewers worried about is the molecule. The other half is the vial: aggregates, synthesis impurities, endotoxin and unverified identity. PeRx MOTS-c is prescribed by a licensed provider after a health screening, compounded at a US-based 503A pharmacy at a fixed 2 mg/mL, and tested for potency and sterility. It ships fully reconstituted and ready to use, so there is no powder to mix and no concentration to work out.

Screening cannot turn unknown risks into known ones, but it catches the situations the mechanism points to, like a sulfonylurea on your medication list, before anything ships. $229 for a one-month supply, syringes and swabs included.

Provider-screened and pharmacy-compounded at a fixed 2 mg/mL.

Shop Now

When to Stop and Contact a Clinician

MOTS-c Side Effects: Common Questions